Can betahistine hydrochloride be used together with pemetinib (pemetinib)?

Betahistine hydrochloride (Betahistine) is a drug commonly used to treat Meniere's disease and other inner ear-related vertigo diseases. Its main mechanism of action is to relieve symptoms such as dizziness and tinnitus by dilating blood vessels in the inner ear and regulating endolymph pressure. In contrast, pemigatinib (Pemigatinib) is an anticancer drug that targets FGFR (fibroblast growth factor receptor) and is suitable for the treatment of certain tumor types such as cholangiocarcinoma that carry FGFR2 fusions or rearrangements. The indications and mechanisms of action of the two are completely different, so they are usually used in clinical practice for different types of patients.

From a pharmacological perspective, betahistine hydrochloride does not participate in cell signaling pathways or DNA synthesis processes, and has no antagonistic effect on targeted tumor therapy. As a small molecule tyrosine kinase inhibitor, pemetinib's metabolism mainly relies on the liver's CYP3A4 enzyme. There are currently no studies or drug instructions suggesting that betahistine hydrochloride will interfere with the metabolic function of CYP3A4, so theoretically there will be no obvious drug interaction between the two in the body.

In actual clinical practice, if a patient suffers from ear symptoms such as dizziness and tinnitus due to tumor treatment, doctors may consider adding betahistine hydrochloride to pemetinib to relieve these atypical symptoms. Under this premise, it is possible to use the two drugs in combination. However, the premise is that the patient does not have severe liver function impairment, because the metabolism of betahistine also depends on liver function. If it is used together with pemetinib, changes in liver function must be closely monitored, especially during long-term medication.

Although there is no known risk of drug interaction between betahistine hydrochloride and pemetinib, any combination of these drugs should be used under the guidance of a physician. Especially for cancer patients with complex physical conditions, the medication plan should comprehensively consider drug metabolism, potential adverse reactions, and individual tolerance. If a patient develops symptoms such as dizziness while taking pemetinib, he or she should first confirm whether it is caused by a side effect of the drug, and then decide whether to add betahistine as a symptomatic treatment drug. Do not add medicine by yourself to avoid affecting the overall treatment effect.

Reference materials:https://www.drugs.com